AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth CareGeographicals
Seasonal Affective DisorderPsychotic DisordersAffective Disorders, PsychoticMood DisordersBipolar DisorderSchizophreniaPhototherapyPsychiatric Status Rating ScalesDelusionsAffectMental DisordersDepressive DisorderSchizophrenic PsychologyAnxiety DisordersDepressive Disorder, MajorPsychoses, Substance-InducedAffective SymptomsDiagnostic and Statistical Manual of Mental DisordersHallucinationsAntipsychotic AgentsSchizophrenia, ParanoidSchizotypal Personality DisorderAntimanic AgentsEmotionsAnxietyCyclothymic DisorderComorbidityAntidepressive AgentsInterview, PsychologicalDelirium, Dementia, Amnestic, Cognitive DisordersDepressionSubstance-Related DisordersProdromal SymptomsNeurotic DisordersCognition DisordersLithium CompoundsParanoid DisordersSuicideLithiumPersonality AssessmentObsessive-Compulsive DisorderSchizophrenic LanguageBrainFreudian TheoryNeuropsychological TestsColor TherapySuicide, AttemptedLithium CarbonateStress Disorders, Post-TraumaticStress, PsychologicalPsychometricsMagnetic Resonance ImagingAttention Deficit Disorder with HyperactivityHospitals, PsychiatricSeverity of Illness IndexPsychotropic DrugsDissociative DisordersAmygdalaAnalysis of VariancePsychiatric Department, HospitalCase-Control StudiesRisk FactorsAge of OnsetSerotonin Plasma Membrane Transport ProteinsChild of Impaired ParentsSomatoform DisordersPersonality DisordersPrevalenceDiagnosis, Dual (Psychiatry)SerotoninGenetic Predisposition to DiseaseConduct DisorderPsychoanalytic TheoryGenotypePrefrontal CortexQuestionnairesCommunity Mental Health CentersSex FactorsFollow-Up StudiesPersonality InventoryCognitionCognitive TherapySleep DisordersBrain MappingMelatoninPedigreeBenzodiazepinesLongitudinal StudiesFacial ExpressionAttentionTryptophan HydroxylaseAlcoholismLife Change EventsRaphe NucleiFamily HealthAutistic DisorderAge FactorsBehavior, AnimalArousalBorderline Personality Disorder

Childhood trauma and hippocampal and amygdalar volumes in first-episode psychosis. (65/123)

 (+info)

Gene therapy for psychiatric disorders. (66/123)

 (+info)

Borderline personality disorder as a female phenotypic expression of psychopathy? (67/123)

 (+info)

Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. (68/123)

High rates of attrition have been reported in randomized controlled trials of patients with severe psychiatric illness, including psychotic depression (MDpsy). The purpose of this study is to examine factors associated with overall attrition and with subtypes of attrition in the Study of the Pharmacotherapy of Psychotic Depression (STOP-PD). Secondary analysis of data collected in a multi-site, randomized, placebo-controlled trial. Clinical services of academic hospitals. Participants comprised 259 persons with MDpsy, aged 18-93 years. The intervention consisted of the random allocation to 12 weeks of treatment of either olanzapine plus sertraline or olanzapine plus placebo. Demographic and clinical variables associated with overall non-completion and sub-types of non-completion of randomized treatment. One hundred and seventeen (45.2%) subjects did not complete 12 weeks of randomized treatment. In a logistic regression analysis, inpatient entry status, olanzapine monotherapy, and higher cumulative medical burden were statistically significant independent predictors of overall non-completion. In a multinomial logistic regression model that examined predictors of subtypes of non-completion, subjects who entered the study as an inpatient were less likely to complete because of inadequate efficacy as determined by the investigator, and older subjects were less likely to complete because of poorer tolerability. Subjects who were assigned to olanzapine monotherapy, younger subjects, and subjects who entered the study as inpatients were less likely to complete because of reasons other than efficacy or tolerability. Understanding factors that contribute to premature discontinuation in studies of MDpsy, and to the specific reasons for attrition, has the potential to improve the management of this disorder, as well as improve the design of future clinical trials of MDpsy.  (+info)

At risk for schizophrenic or affective psychoses? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. (69/123)

 (+info)

Childhood infection and adult schizophrenia: a meta-analysis of population-based studies. (70/123)

 (+info)

The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. (71/123)

 (+info)

Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. (72/123)

 (+info)